4D-150

Neovascular age-related macular degeneration

Manufacturer: 4D Molecular Therapeutics
Regulatory submission: Not announced
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description

Product information

81 evidence topics · 40 sources

Generic, brand name and therapeutic class of product2 evidence topics · 4 sources
Dosage forms and strengths3 evidence topics · 3 sources
Average sales price and wholesale acquisition cost7 evidence topics · 7 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication3 evidence topics · 3 sources
Pharmacology16 evidence topics · 5 sources
Contraindications/Warnings/Precautions/Adverse effects11 evidence topics · 5 sources
Special populations3 evidence topics · 1 source
Drug/Drug, drug/disease interactions1 evidence topic · 2 sources
Dosing and administration6 evidence topics · 10 sources
Access and distribution4 evidence topics · 4 sources
Co-prescribed/Concomitant therapies4 evidence topics · 4 sources
Effect of 4D-150 on quality measures1 evidence topic · 1 source
Product comparison19 evidence topics · 18 sources